UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom.
Diamond Light Source, Harwell Science and innovation Campus, Didcot, Oxfordshire OX11 0DE, United Kingdom.
Mol Pharm. 2022 May 2;19(5):1477-1487. doi: 10.1021/acs.molpharmaceut.2c00016. Epub 2022 Mar 29.
Flufenamic acid (FFA) is a highly polymorphic drug molecule with nine crystal structures reported in the Cambridge Structural Database. This study explores the use of synchrotron X-ray powder diffraction combined with differential scanning calorimetry to study crystallization and polymorphic phase transitions upon heating FFA-polymer amorphous solid dispersions (ASDs). Ethyl cellulose (EC, 4 cp) and hydroxypropylmethylcellulose (HPMC) grades with different viscosities and substitution patterns were used to prepare dispersions with FFA at 5:1, 2:1, 1:1, and 1:5 w/w drug/polymer ratios by quench cooling. We employed a 6 cp HPMC 2910 material and two HPMC 2208 samples at 4000 and 100 000 cp. Hyphenated X-ray diffraction (XRD)-differential scanning calorimetry (DSC) studies show that the 6 and 100 000 cp HPMCs and 4 cp EC polymers can stabilize FFA form IV by inhibiting the transition to form I during heating. It appears that the polymers stabilize FFA in both amorphous and metastable forms via a combination of intermolecular interactions and viscosity effects. Increasing the polymer content of the ASD also inhibits polymorphic transitions, with drug/polymer ratios of 1:5 w/w resulting in FFA remaining amorphous during heating. The comparison of FFA ASDs prepared with different samples of HPMCs and ECs suggests that the chemical substitution of the polymer (HPMC 2208 has 19-24% methoxy groups and 4-12% hydroxypropyl groups, while HPMC 2910 has 28-30% methoxy groups and 7-12% hydroxypropyl groups) plays a more significant role in directing polymorphic transitions than the viscosity. A previously unreported polymorph of FFA was also noted during heating but its structure could not be determined.
氟芬那酸(FFA)是一种高度多晶型药物分子,在剑桥结构数据库中报告了九个晶体结构。本研究探索了使用同步加速器 X 射线粉末衍射结合差示扫描量热法研究 FFA-聚合物无定形固体分散体(ASD)在加热时的结晶和多晶型相变。使用不同粘度和取代模式的乙基纤维素(EC,4 cp)和羟丙基甲基纤维素(HPMC)级分,通过淬火冷却制备 FFA 与聚合物的 5:1、2:1、1:1 和 1:5 w/w 药物/聚合物比的分散体。我们使用了一种 6 cp HPMC 2910 材料和两种 HPMC 2208 样品,其粘度分别为 4000 和 100000 cp。X 射线衍射(XRD)-差示扫描量热法(DSC)研究表明,6 和 100000 cp HPMCs 和 4 cp EC 聚合物可以通过抑制加热过程中向 I 型转变来稳定 FFA 形式 IV。似乎聚合物通过分子间相互作用和粘度效应的组合来稳定无定形和亚稳形式的 FFA。增加 ASD 中聚合物的含量也会抑制多晶型转变,当药物/聚合物比为 1:5 w/w 时,FFA 在加热过程中保持无定形。用不同 HPMC 和 EC 样品制备的 FFA ASD 的比较表明,聚合物的化学取代(HPMC 2208 具有 19-24%的甲氧基和 4-12%的羟丙基,而 HPMC 2910 具有 28-30%的甲氧基和 7-12%的羟丙基)在指导多晶型转变方面比粘度更重要。在加热过程中还注意到了一种以前未报道的 FFA 多晶型,但无法确定其结构。